Healthcare Industry News:  Biliary Stent 

Devices Interventional Regulatory

 News Release - March 3, 2009

Flexible Stenting Solutions, Inc. Receives CE Mark for New FlexStent Biliary Self Expanding Stent System

EATONTOWN, N.J.--(HSMN NewsFeed)--Flexible Stenting Solutions, Inc. (“FSS”), a leading developer of next-generation flexible stents, announced today it has received CE Mark (Conformité Européene) for its FlexStent™ Biliary Self Expanding Stent System. Stent sizes include a complete matrix of 5, 6, 7 and 8 mm diameters with 30 through 120 mm lengths in a 6 French delivery system.

The FlexStent™ Biliary Self Expanding Stent System is indicated for the palliative treatment of biliary strictures resulting from malignant neoplasms. The key to FSS stent technology is the integration of helically wound struts with helical flexible coils. The key to the delivery technology is simplicity, ease of use and placement.

Janet Burpee, FSS’s CEO, stated: “Our FlexStent™ Biliary Self Expanding Stent System offers the physician a straight forward solution for biliary duct stenting.” She added, “We currently have a reconstrainable system under development which will offer the gastroenterologist the additional security of knowing repositioning is at his/her fingertips.”

In addition to the CE Mark, FSS has submitted Section 510(k) Notification to U.S. Food and Drug Administration and is awaiting 510(k) clearance for this system. FDA clearance will allow for the sale of the device in the U.S.

About Flexible Stenting Solutions Inc.

Flexible Stenting Solutions, Inc. is a leading developer of next generation vascular and Biliary Stents. Our fully connected stent has coupled technology with clinical needs by providing a highly durable and fatigue resistant stent with superior radial stiffness, flexibility and conformability. The company’s lead vascular product is the FlexStent™ Femoropopliteal Self Expanding Stent System specifically designed for the harsh loading conditions present in the dominant sites of peripheral vascular disease in the lower extremity. For more information about Flexible Stenting Solutions, Inc. please visit the company’s website at

This press release contains forward-looking statements that are based upon management’s current expectations and are inherently uncertain. Actual results may differ materially from anticipated results.

Source: Flexible Stenting Solutions

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.